TARA News & Events

Protara Therapeutics highlighted recent updates and anticipated 2026 milestones. Milestones include: On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026; Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026; Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026; Recently completed approximately $86 million public offering extending cash runway into 2028

Protara Therapeutics, announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous Choline Chloride in patients receiving long-term parenteral support. IV Choline Chloride, the Company's investigational phospholipid substrate replacement therapy, was previously granted Fast Track designation by the U.S. Food and Drug Administration.